Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Current and emerging treatment options for MDS

Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, comments on current and emerging treatment options for myelodysplastic syndromes (MDS). Currently, numerous promising agents are progressing through clinical trials, with several options predicted to change clinical practice in the coming years. Dr Garcia highlights sabatolimab, magrolimab, and combined venetoclax plus azacitidine as exciting therapies discussed at ASH 2021. Data from several negative trials were also presented, including the PANTHER trial (NCT03268954) of pevonedistat plus azacitidine versus single-agent azacitidine in high-risk MDS, which Dr Garcia shares her thoughts on. Dr Garcia also comments on data from The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1102 study (NCT02016781), comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients with advanced MDS. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.